OPKO Completes Acquisition of Bio-Reference Laboratories

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE: OPK) and BioReference Laboratories, Inc. (NASDAQ: BRLI) today announced the completion of the acquisition of BioReference by OPKO. Shareholders of BioReference will receive 2.75 shares of OPKO common stock for each share of BioReference common stock.  “The acquisition of Bio-Reference is important for OPKO,” commented Dr. Phillip Frost, OPKO’s Chairman and Chief […]

OPKO Lab Signs Contracts with Leading Preferred Provider Networks for Laboratory Testing Services Including the 4Kscore® Test

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) today announced that it has entered into agreements with Stratose, Three Rivers Provider Network and Fortified Provider Network for testing services from OPKO Lab, including the 4Kscore®Test, the only blood test that accurately identifies an individual patient’s risk for high-grade, aggressive cancer. The cumulative contracts, with some of the largest healthcare PPO network […]

OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned Acquisition

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (OPK) and Bio-Reference Laboratories, Inc. (BRLI), today announced that early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) has been granted, effective 1 de julio de 2015, for OPKO’s planned acquisition of Bio-Reference. This Smart News Release features multimedia. View the full release here: www.businesswire.com/news/home/20150702005579/en/ Expiration of the waiting period […]

OPKO 4Kscore® Recommended in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) today announced the decision of the National Comprehensive Cancer Network (NCCN) to include 4Kscore® as a recommended test in the 2015 NCCN Guidelines for Prostate Cancer Early Detection. The panel concluded that the 4Kscore, as a blood test with greater specificity over the PSA test, is indicated for use prior to a first […]

OPKO and Bio-Reference Laboratories To Hold Joint Conference Call to Discuss Merger

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) and Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) will host a joint conference call and webcast at 8:30 a.m. ET on Thursday, 11 de junio de 2015, to discuss the previously announced entry into a merger agreement for OPKO to acquire Bio-Reference Laboratories and to discuss Bio-Reference Laboratories’ second quarter financial results. This joint call will be in lieu of the separate earnings […]

Powered by Translations.com GlobalLink OneLink Software